Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
3.825
-0.055 (-1.42%)
At close: Sep 8, 2026, 4:00 PM EDT
3.700
-0.180 (-4.64%)
Pre-market: Sep 9, 2026, 7:36 AM EDT
Galmed Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
3.83M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PMGC Holdings | 2.58M |
| 60 Degrees Pharmaceuticals | 1.21M |
| GeoVax Labs | 852.28K |
| BioRestorative Therapies | 357.87K |
| Addex Therapeutics | 136.51K |
| VivoSim Labs | 112.00K |
| Silo Pharma | 54.08K |
| Alaunos Therapeutics | 3.00K |
GLMD News
- 4 minutes ago - Galmed announces name change to Eocene - TheFly
- 21 days ago - Colospan completes feasibility study of new assesment platform - TheFly
- 21 days ago - Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology - PRNewsWire
- 21 days ago - Galmed trading halted, news pending - TheFly
- 22 days ago - Galmed reports results from study of a combination of Aramchol and Xtandi - TheFly
- 22 days ago - Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models - PRNewsWire
- 6 weeks ago - Galmed’s Aramchol ODF formulation shows positive results in Parkinson’s - TheFly
- 6 weeks ago - Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market - PRNewsWire